In an interview conducted during the 2021 European School of Hematology (ESH) 7th Translational Research E-Conference on Myelodysplastic Syndromes, Felicitas Thol, MD, Hannover Medical School, Hannover, Germany, discusses current and emerging treatment options for MDS. Dr Thol presents results from clinical trials designed to investigate the combination of azacitidine and venetoclax for patients with high-risk MDS. Additionally, APR-246 may provide a future option for patients with TP53-mutant, high-risk MDS. For patients with low-risk MDS, Dr Thol notes that a new “don’t eat me” signal destroyer is in development, as well as novel therapies designed to target inflammation in order to prevent bone marrow failure.